The Hippo signaling network is proving to be an essential regulator within the cell, participating in multiple cellular phenotypes including cell proliferation, apoptosis, cell migration and organ size control. Much of this pathway is conserved from flies to mammals; however, how the upstream components, namely Expanded, affect downstream processes in mammalian systems has remained elusive. Only recently has human Expanded (hEx), also known as FRMD6 or Willin, been identified. However, its functional significance with respect to its putative tumor suppressor function and activation of the Hippo pathway has not been studied. In this study, we show for the first time that hEx possesses several tumor suppressor properties. First, hEx dramatically inhibits cell proliferation in two human cancer cell lines, MDA-MB-231 and MDA-MB-436 cells, and sensitizes these cells to the chemotherapeutic drug Taxol. Furthermore, downregulation of hEx in the immortalized MCF10A breast cell line leads to enhanced proliferation and resistance to Taxol treatment. As evidence for its tumor suppressor function, overexpression of hEx inhibits colony formation, soft agar colony growth in vitro and in vivo tumor growth in nude mice. Although Drosophila expanded (ex) can activate the Hippo pathway, surprisingly no significant alterations were discovered in the phosphorylation status of any of the Hippo pathway components, including downstream tumor suppressor LATS1, upon overexpression of hEx. In addition, knockdown of both LATS1 and LATS2 in hEx-overexpressing cells was unable to rescue the hEx phenotype, suggesting that hEx functions independently of the Hippo pathway in this cell line. Alternatively, we propose a mechanism through which hEx inhibits progression through the S phase of the cell cycle by upregulating p21
Introduction
A mutated expanded (ex) gene was originally identified in 1926 and shown to enhance the growth of imaginal discs in Drosophila, suggesting that ex functions as a tumor suppressor (Stern and Bridges, 1926) . Since then, ex has been definitely classified as a tumor suppressor due to its abilities to restrict growth, differentiation and enhance apoptosis in the wings and eyes of flies (Boedigheimer and Laughon, 1993; Blaumueller and Mlodzik, 2000; McCartney et al., 2000) . Due to the similar overgrowth phenotypes seen in the imaginal discs of flies exhibiting mutations in the core Hippo pathway components, ex was added as a key player in this pathway (Hamaratoglu et al., 2006) .
The evolutionarily conserved Hippo signaling pathway is an area of intense research due to its fundamental roles in organ size control and tumorigenesis (Zhao et al., 2010) . In Drosophila, the Ser/Thr kinases Hippo (hpo) and dlats along with adapter proteins sav and mats make up the core components. In this system, active Hpo phosphorylates and activates dlats, enhanced by interacting sav and mats. The primary target is Yki, a transcriptional co-activator and oncogene whose overexpression phenocopies loss of dlats. Several downstream targets of Yki have been described, including bantam, cyclin E and diap1. Activation of this pathway involves the WW and C2-domain containing protein Kibra and two FERM domain proteins ex and mer, which all localize to the apical membrane and cooperatively promote dlats phosphorylation and activation. Connecting these membrane-associated proteins with external growth cues is the atypical cadherin fat or the apical transmembrane protein crumbs, both of which activate ex (reviewed in Pan, 2010 and Halder and Johnson, 2011) .
Importantly, most of this pathway is conserved in mammalian systems. Hpo homologs MST1 and MST2 phosphorylate and activate LATS1 and LATS2 (Chan et al., 2005) . Once activated LATS1/LATS2 bind and phosphorylate the Yki homolog YAP or its paralog TAZ, inhibiting their transcriptional activity (Hao et al., 2008; Lei et al., 2008) . Numerous transcriptional targets for LATS1 and LATS2 (Visser and Yang, 2010a) as well as YAP (Ota and Sasaki, 2008; Zhao et al., 2008) and TAZ (Lai et al., 2011) have been identified with several proven to mediate key Hippo pathway functions. Although this core kinase cascade is well conserved, upstream regulation of the mammalian Hippo pathway is less understood. Homologs exist for each membraneassociated protein: Merlin/NF2 for mer, FRMD6/ Willin/Human Expanded (hEx) for ex, KIBRA for Kibra as well as FAT4 for fat and Crumbs1-3 for Crumbs. Although Merlin/NF2 is a well-characterized tumor suppressor and has been shown to enhance LATS1/2 phosphorylation (Lau et al., 2008; Yu et al., 2010) and human KIBRA has also been found to bind LATS1 and LATS2 enhancing their phosphorylation and kinase activity (Yu et al., 2010; Xiao et al., 2011) , thereby functioning in parallel to their Drosophila homologs, little is known about hEx in human systems.
hEx is a FERM domain protein similar to Merlin and the ERM (Ezrin, Radixin, Moesin) family of cytoskeletal crosslinkers and is localized throughout the cytoplasm or along the plasma membrane (Gunn-Moore et al., 2005) . In this study, we outline the key cellular functions of hEx and suggest that hEx possesses tumor suppressor properties. By analyzing individual components of the Hippo pathway, we provide the first evidence that hEx does not activate or function through this pathway, suggesting that the upstream regulation of the Hippo pathway in MDA-MB-231 cells is not conserved. This study is the first to characterize hEx and provides novel insights into its functions.
Results and discussion
To examine the cellular functions of hEx in breast cancer cell lines, we established hEx-expressing MDA-MB-231 cell lines using lentivirus expressing vector alone (WPI) or FLAG-tagged hEx (Figure 1a ). MDA-MB-231 is an aggressive breast cancer cell line but when hEx is overexpressed their growth is severely inhibited (Figure 1b) . Importantly, this phenotype is specific to expression of hEx and not due to any non-specific virus effects since knockdown of hEx in the hEx-overexpressing cells (hEx-shEx) using lentivirus expressing shRNA targeting hEx completely reverses the growth inhibitory phenotype. To show the effect of hEx on cell proliferation is not cell line specific, we repeated these experiments using another aggressive breast cancer cell line MDA-MB-436 ( Figure 1c) . As with the MDA-MB-231 cells, expression of hEx dramatically inhibits MDA-MB-436 cell proliferation whereas the hEx-shEx cell line proliferates at a similar rate compared with the WPI control cell line (Figure 1d ). In addition, hEx inhibits cell proliferation in a dose-dependent manner (Supplementary Figure S1 ), showing that rates of cell proliferation correlate with hEx expression.
Traditionally, tumor suppressors are defined by their loss of function in cancer. To recapitulate this in our cell system we downregulated endogenous hEx in the MCF10A immortalized breast cell line using lentivirus expressing vector alone (pLKO.1) or one of the two shRNAs targeting hEx for degradation (shEx-1 and shEx-2). Due to the understudied nature of hEx, a reliable antibody for hEx does not exist. Therefore, to assess the relative levels of hEx in MCF10A cells we used qRT-PCR to measure mRNA levels and show that 0 ; shEx-2, 5 0 -CCACAGACTATATGTCGGAAA-3 0 ). mRNA was extracted and qRT-PCR was performed as previously described (Visser and Yang, 2010a ) using rRNA as internal control. (f) Cell proliferation analysis was performed as described above.
hEx functions as a tumor suppressor in human cancer cell lines S Visser-Grieve et al hEx expression is reduced ( Figure 1e ; Supplementary Figure S2 ). Significantly, when hEx is downregulated, the rate of proliferation in MCF10A cells dramatically increases (Figure 1f ), providing final evidence that hEx is directly involved in regulating cell proliferation. In addition to the importance of cell proliferation in tumor progression, apoptosis also has a vital role, both in eliminating tumor cells during the early onset of tumorigenesis, as well as during the development of drug resistance. A widely used chemotherapeutic in the treatment of breast and ovarian cancer is the microtubule inhibitor Taxol (McGrogan et al., 2008) . Using the MDA-MB-231 stable cell lines expressing hEx, cells were treated with increasing concentrations of Taxol. As shown in Figure 2a , although the control cells are relatively resistant to Taxol with a maximum 28.53±3.46% cell death after treatment with 200 nM Taxol, cells expressing hEx were significantly more sensitive with 42.03 ± 2.97% cell death. Importantly, knockdown of hEx in hEx-expressing cells is also resistant to Taxol with a maximum of 29.29 ± 3.21% cell death. Similar results were also obtained when cells were treated with lower concentrations of Taxol, showing that sensitivity to Taxol correlates with hEx expression (Figure 2a) .
A role of hEx in mediating drug response is further supported by analysis of the MCF10A cells with reduced hEx expression. Compared with MDA-MB-231 cells, the MCF10A cells are relatively sensitive to Taxol treatment, a property consistent with their non-tumorigenic nature. However, when hEx expression is reduced, the cells become resistant to Taxol treatment (Figure 2b ). Unlike control cells (pLKO.1) that respond dramatically to low concentrations of Taxol with significantly increasing cell death with increasing Taxol concentrations, both shEx-1 and shEx-2 have very little cell death at low drug concentrations. The most dramatic difference is seen at 10 nM Taxol with 39.26 ± 4.60% cell death in pLKO-1 expressing MCF10A cells compared with an almost twofold reduction in cell death in both shEx-1 and shEx-2 cell lines with 23.04 ± 1.51 and 23.33 ± 1.06% cell death, respectively. This is the first evidence to delineate the cellular functions of hEx, showing that hEx not only regulates cell proliferation but also is an important mediator of drug response.
The acquisition of the sustained proliferative and apoptotic resistance properties exhibited by cells with downregulated hEx levels is reminiscent of key hallmarks of tumor cells (Hanahan and Weinberg, 2011) . This prompted us to assess the ability of hEx to function as a tumor suppressor in vitro. Initial analysis with a clonogenic assay measuring the ability of single cells to form clones, a property attributed to tumor cells, demonstrated that whereas the control MDA-MB-231 breast cancer cells expressing vector alone (WPI) were able to efficiently form colonies after 10 days with a total number of 325 ± 34 colonies, expression of hEx significantly inhibited the formation of colonies with a total number of only 192±31 colonies ( Figure 3a) . As before, loss of hEx in the hEx-overexpressing line rescues the ability of cells to form colonies with 309 ± 49 colonies.
Transformation assays provided further evidence that hEx functions as a tumor suppressor in cancer cell lines. Expression of hEx severely inhibited the ability of MDA-MB-231 cells to form colonies in soft agar with only 24 ± 16 colonies formed compared with 86 ± 11 colonies formed in the WPI control cells and 77 ± 19 colonies in the hEx-shEx cell line (Figure 3b ). On the other hand, loss of hEx in the non-tumorigenic MCF10A cell line causes transformation of these cells. Where essentially no colonies form in vector control pLKO.1 cells (12 ± 3), there is a significant increase in anchorage-independent growth in both shEx-1 (78 ± 9) and shEx-2 (52±7) cell lines (Figure 3c ). Finally, in vivo, hEx can dramatically inhibit tumor growth in mouse xenograph models (Figures 3d and e) . These results are consistent with Drosophila models where ex has also been implicated in cell growth and apoptosis as functions of its tumor suppressor activity. In fact, some of the first studies on ex showed that it regulated cell proliferation in the imaginal discs in the developing flies and when overexpressed led to decreased cell number in the wings (Boedigheimer et al., 1997). In addition, further studies also suggested that where overexpression of ex induces cell death (Blaumueller and Mlodzik, 2000) , loss of ex along with its FERM domain partner mer suppressed apoptosis in the developing eye (Hamaratoglu et al., 2006) . Together, the enhanced proliferation and the loss of apoptosis in ex mutant flies lead to tumor overgrowth. Although the Hippo pathway is more complex in mammalian systems, the proliferation, apoptosis and tumor suppressive functions of hEx are similar to several human Hippo pathway members. Not only are LATS1 and LATS2 considered tumor suppressors (Visser and Yang, 2010b) , but also in cell lines overexpression of either LATS1 or LATS2 inhibits proliferation and induces cell death (Yang et al., 2001; Xia et al., 2002; Li et al., 2003) , and we have shown that loss of both LATS1 and LATS2 enhances cell proliferation and renders cells resistant to Taxol (Visser and Yang, 2010a) . In addition, phosphorylation and expression of both downstream targets YAP (Li et al., 2011) and TAZ (Chan et al., 2008; Lai et al., 2011) have been associated with breast tumor progression and Taxol sensitivity.
Because expanded is an upstream component of the evolutionarily conserved Drosophila Hippo pathway, we wanted to determine if hEx functions in an evolutionarily conserved manner by activating the Hippo pathway. In Drosophila, ex expression leads to enhanced phosphorylation and activation of dlats and subsequent phosphorylation and inhibition of yorkie (Hamaratoglu et al., 2006; Yu et al., 2010) . Surprisingly, when we assessed the relative phosphorylation levels of the mammalian Hippo pathway components, including MST1/2, LATS1, YAP and TAZ, in hEx-overexpressing MDA-MB-231 cells we found no significant differences (Figure 4a ). Upon stimulation, MST1 and MST2 autophosphorylate on conserved threonine residues (Radu and Chernoff, 2009 ) and once active, phosphorylate LATS1 on T1079 leading to LATS1 autophosphorylation on S909 (Chan et al., 2005) . Once active, LATS1 phosphorylates YAP on S127 (Hao et al., 2008) and TAZ on S89 (Lei et al., 2008) . Using specific antibodies for these phosphorylation sites, it is evident that hEx does not significantly enhance the phosphorylation of the canonical Hippo pathway. To further confirm that hEx does not function through this pathway, we knocked down the central kinases LATS1 and LATS2 in hEx-expressing MDA-MB-231 cells (Figure 4b ) and show that loss of LATS1 and LATS2 was not able to alter the inhibitory effect of hEx on cell proliferation (Figure 4c) . Therefore, unlike in Drosophila, where loss of dlats rescues the ex phenotype (Feng and Irvine, 2007) , hEx tumor suppressor function is independent of the Hippo pathway.
Importantly, although much of the Hippo pathway is conserved from flies to humans, complexity increases moving up the evolutionary tree. Therefore, differences can arise in proteins structure, interactions and function. Importantly, evidence already exists to support this hypothesis. Although hEx is the closest human homolog to ex, their structure is considerably different. hEx and Drosophila ex share the conserved FERM domain, but hEx lacks the C-terminal region of Drosophila ex which contains several PPXY motifs responsible for hEx functions as a tumor suppressor in human cancer cell lines S Visser-Grieve et al protein-protein interactions (Gunn-Moore et al., 2005; Badouel et al., 2009) . Interestingly, it has been suggested that the tumor suppressor function of Drosophila ex is mediated primarily via its C-terminus (Pellock et al., 2007) , which is further evidence that hEx and Drosophila ex, although both tumor suppressors, mediate their effects by distinct mechanisms.
In addition, disparities between Drosophila and human systems have been shown in both the downstream transcriptional targets and the upstream regulatory proteins of the Hippo pathway. For example, cyclin E, diap1 and bantam are key genes downstream of Yki in Drosophila (Zhao et al., 2010 ), but have not been shown to be transcriptional targets of its orthologs (Ota and Sasaki, 2008; Zhao et al., 2008; Lai et al., 2011) . Additionally, whereas dRASSF antagonizes the Hippo pathway in Drosophila (Polesello et al., 2006) , its mammalian homolog RASSF1A activates MST1/2 and the kinase cascade (Guo et al., 2007) . Also upstream, Drosophila Kibra interacts with multiple Hippo pathway components including mer, ex, hpo and dlats. However, its human homolog binds only Merlin but not MST2 or hEx (Genevet et al., 2010; Yu et al., 2010) . Together, this suggests that although the core Hippo kinase cassette is conserved, both the mediators and regulators of this pathway are more diverse in mammalian systems.
Understanding the mechanisms mediating hEx function is essential. To this end, we propose a model whereby hEx suppresses S-phase progression by upregulating p21
Cip1 and downregulating Cyclin A. Cell-cycle analysis of hEx-overexpressing MDA-MB-231 cells shows an accumulation of cells in the S phase with a concomitant decrease in the G2 phase (Figure 4d ). To assess the mechanism, we surveyed the expression of a panel of cell-cycle proteins. Expression of hEx most significantly increases p21
Cip1 and decreases Cyclin A expression (Figure 4e ). The p21
Cip1 cyclin kinase inhibitor has pleiotrophic effects, affecting all stages of cellcycle progression (Jung et al., 2010) , and the ability of p21
Cip1 to inhibit S-phase progression has been linked to the downregulation of Cyclin A expression (Ogryzko et al., 1997) .
In summary, this work characterizes the cellular functions of hEx protein in cancer cell lines and shows that it is a potent inhibitor of cell proliferation, transformation and modulator of drug sensitivity. This suggests that hEx has tumor suppressor properties and future work should confirm this nature of hEx through mutational studies and/or clinical cancer sample analysis. Importantly, hEx functions in a Hippo-independent manner, shedding new light on distinct Hippo signaling pathways in flies and mammals.
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